Biotech

All Articles

Ascendis' dwarfism medicine smash hits in period 3, threatens BioMarin

.Ascendis Pharma has emerged as a potential threat to BioMarin's Voxzogo, reporting period 3 growth ...

Despite ph. 3 skip, Alkeus finds course in advance for eye disease asset

.Though Alkeus Pharmaceuticals' oral eye disease property stopped working to considerably decrease g...

Kairos goes public along with $6M IPO to fund trials of cancer drug

.With a trio of biotechs reaching the Nasdaq on Friday, it was actually effortless to skip a smaller...

Vaccine as well as Keytruda combo efficient in squamous tissue cancer

.Immune system gate inhibitors are the superheroes of cancer therapy. Drugs like Bristol Myers Squib...

Cue Biopharma mark time J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, firings ...

Regeneron's Opdualag competitor shows 57% reaction cost

.Regeneron is actually back along with long-term consequence for its own LAG-3 inhibitor and also PD...

AstraZeneca posts records on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early take a look at the performance of its internal antibody-drug con...

iTeos- GSK's TIGIT superstar presents relevant remodeling

.After revealing a stage 3 launch based on beneficial midstage results, iTeos and also GSK are ultim...

More collective FDA can easily increase unusual condition R&ampD: document

.The FDA must be much more available and joint to unleash a rise in commendations of rare illness me...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It is actually an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as we...